Cells, Volume 13, Issue 12
2024 June-2 - 80 articles
Cover Story: The cell-penetrating peptide Dpep targets transcription factors ATF5, CEBPB and CEBPD to kill a wide range of cancer (but not normal) cells in vitro and in vivo. We find that Dpep compromises glucose uptake and glycolysis in a tumor cell context-dependent manner. These actions are dependent on the induction of the tumor suppressor TXNIP (thioredoxin-interacting protein) mRNA and protein, contributing to cancer cell apoptotic death. Given Dpep’s inhibitory actions on glucose uptake and glycolysis, we assessed its cytotoxicity on tumor cells in combination with the clinically approved drugs metformin and atovaquone, which inhibit oxidative phosphorylation. The combinations proved to have additive to synergistic activities on all of the lines tested. These findings extend our understanding of Dpep’s apoptotic mechanism and support its use in cancer therapies. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.